Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer - A multicentre, open, controlled, prospectively randomised trial

European Journal of Cancer

Volumn 38, Issue 17, 2002, Pages 2265-2271

  Von Minckwitz, G ^a   Loibl, S ^a   Brunnert, K ^b   Kreienberg, R ^c   Melchert, F ^d   Mosch R ^e   Neises, M ^d   Schermann, J ^f   Seufert, R ^g   Stiglmayer, R ^h   Stosiek, U ⁱ   Kaufmann, M ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MarienHospital Osnabruck   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Frauenklinik Baden ^*  (Germany)

^f Akademisches Lehrkrankenhaus U   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h Krankenhaus St Trudpert gGmbH   (Germany)

ⁱ Krankenhaus der Evang Diakonissenanstalt   (Germany)

Author keywords

Adjuvant therapy; Endometrial cancer; Medroxyprogesterone acetate; Randomised trial; Tamoxifen

Indexed keywords

MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE SEVERITY; ENDOMETRIUM CARCINOMA; EVALUATION; HORMONAL THERAPY; HOT FLUSH; HUMAN; LUNG EMBOLISM; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STROKE; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0036850351     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00378-7     Document Type: Article

References (32)

1. Emons G., Heyl W. Hormonal treatment of endometrial cancer. J. Cancer Res. Clin. Oncol. 126:2000;619-623.
2. Creasman W., Odicino F., Maisonneuve P.et al. Carcinoma of the corpus uteri. J. Epidemiol. Biostat. 3:1998;35-61.
3. Thigpen J.T. Systemic therapy with single agents for advanced or recurrent endometrial carcinoma. Surwit E.A., Alberts D.S. Endometrial Cancer. 1989;93-106 Kluwer Academic, Boston.
4. Hoskins P.J., Swenerton K.D., Pike J.A.et al. Paclitaxel and Carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer. a phase II study J Clin Oncol. 19:2001;4048-4053.
5. Thigpen J.T., Brady M.F., Alvarez R.D.et al. Oral Medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma. a dose response study by the gynecologic oncology group J. Clin. Oncol. 17:1999;1736-1744.
6. Lewis G.C., Slack N.H., Mortel A., Bross I.D. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol. Oncol. 2:1974;368-376.
7. McDonald R.R., Thorogood J., Mason M.K. A randomised trial of progestogens in the primary treatment of endometrial carcinoma. Br. J. Obstet. Gynaecol. 93:1988;166-174.
8. Urbanski K., Karolewski K., Kojs Z. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one institutional prospective clinical trial. Eur. J. Gynaec. Oncol. 14:1993;98-104.
9. Jordan V.C., Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer. 11:1975;205-206.
10. Rose P.G. Medical progress. endometrial carcinoma N. Engl. J. Med. 335:1996;640-648.
11. Creasman W.T., Odicino F., Maisonneuve P.et al. Carcinoma of the corpus uteri. J. Epidemiol. Biostat. 6:2001;47-86.
12. von Minckwitz G., Kühn W., Kaufmann M.et al. Prognostic importance of DNA-ploidy and S-phase fraction in endometrial cancer. Int J Gynecol Cancer. 4:1994;250-256.
13. Vergote I., Kjorstad K., Abelar V., Kolstad P. A randomised trial of adjuvant progestagen in early endometrial cancer. Cancer. 64:1989;1011-1016.
14. Burke T.W., Wolfson A.H. Limited endometrial carcinoma. adjuvant therapy Sem. Oncol. 21:1994;84-96.
15. COSA-NZ-UK Endometrial Cancer Study Group Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int. J. Gynecol. Cancer. 8:1998;387-391.
16. Jain M.G., Rohan T.E., Howe G.R., Miller A.B. A cohort study of nutritional factors and endometrial cancer. Eur. J. Epidemiol. 16:2000;899-905.
17. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma. a Gynecologic Oncology Group study J. Clin. Oncol. 19:2001;364-367.
18. Moore T.D., Phillips P.H., Nerenstone S.R., Cheson B.D. Systemic treatment of advanced and recurrent endometrial carcinoma. current status and future directions J. Clin. Oncol. 27:1991;1295-1300.
19. Cuzick J., Baum M. Tamoxifen and contralateral breast cancer. Lancet. 2:1985;282.
20. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer. an overview of the randomised trials Lancet. 351:1998;1451-1467.
21. Joensuu H., Holli K., Oksanen H., Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res. Treat. 63:2000;225-234.
22. McDonald C.C., Alexander F.E., Whyte B.W., Forrest P.A., Stewart H.J. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br. Med. J. 311:1995;977-980.
23. Constantino J.P., Kuller L.H., Ives D.G., Fisher B., Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J. Natl. Cancer Inst. 89:1997;747-749.
24. Fornander T., Rutquist L.E., Cedarmark B.et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancer. Lancet. 1:1989;117-120.
25. Fisher B., Constantino J.P., Redmond C.K.et al. Endometrial cancer in tamoxifen treated breast cancer patients. findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 86:1994;527-537.
26. Powles T.J., Eales S.A., Ashley S.E.et al. Interim analysis of the incident breast cancer in The Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 362:1998;98-101.
27. Love R.R., Kurtycz D.F., Dumesic D.A., Laube D.W., Yang Y. The effects of tamoxifen on the vaginal epithelium in postmenopausal women. J. Womens Health Gend. Based Med. 9:2000;559-563.
28. Gerber B., Krause A., Müller H.et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J. Clin. Oncol. 18:2000;3457-3458.
29. Assikis V.J., Neven P., Jordan V.C., Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur. J. Cancer. 32A:1996;1464-1476.
30. O'Regan RM, England GM, Cisneros A, Jordan V. Relationship of tamoxifen and the growth of tamoxifen-stimulated tumors. Proc ASCO 1998, 17, 109a (abstr 419).
31. Kaufmann M., von Minckwitz G. New hormones. Bonnadonna G., Hortobagyi G.N., Gianni A.M. Textbook of Breast Cancer - A Clinical Guide to Therapy. 1997;218-304 Martin Dunitz, London.
32. Podczaski E., Mortel R. Hormonal treatment of endometrial cancer. past, present, future Best Pract. Res. Clin. Obstet. Gynaecol. 15:2001;469-489.